Correction to: Preclinical Development of Near-Infrared-Labeled CD38-Targeted Daratumumab for Optical Imaging of CD38 in Multiple Myeloma (Molecular Imaging and Biology, (2021), 23, 2, (186-195), 10.1007/s11307-020-01542-4)

The original online version of this article was revised to remove a duplicate image in Figure 3 and to revise Figure 2. The original article has been corrected. (Figure presented.) (Figure presented.) High contrast observed with DARA-IRDye800 at longer time points in MM.1S SQ mice. a Representative GFP and IRDye800 in vivo images of MM.1S SQ mice 2 and 7 days post-administration of DARA-IRDye800. b Calculated TBRs in MM.1S SQ mice across individual time points of DARA-IRDye800. c Normalized biodistribution (%ID/g) at 2 and 7 days postadministration of DARA-IRDye800 in non-tumor and MM.1S SQ mice. n = 5/group. Two-way ANOVA followed by Sidak’s multiple comparisons test was performed on biodistribution data. **p < 0.01; ****p < 0.0001. a.u., arbitrary units DARA-IRDye800 allows for non-invasive imaging of cancerous bone marrow regions in MM.1S IV mice. Representative images of GFP and IRDye800 fluorescence in vivo of a femur, b skull, and c spine in separate MM.1S IV mice 7 days postadministration of DARA-IRDye800. a.u., arbitrary units.